Journals / BEYOGLU EYE JOURNAL / 2022 / Cilt: 7 - Sayı: 2

Choroidal Neovascularization Associated with Best Vitelliform Macular Dystrophy

Pages
103–108
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The IRF is a marker that can be used both in the diagnosis and treatment monitoring of CNV associated with BVMD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The aim of the study was to evaluate the clinical and optical coherence tomography (OCT) findings of patients with choroidal neovascularization (CNV) due to best vitelliform macular dystrophy (BVMD).
📊
Key Findings & Data:Results: One (16%) of the cases was female and five (83%) were male.
💡
Conclusion & Impact:The IRF is a marker that can be used both in the diagnosis and treatment monitoring of CNV associated with BVMD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: The aim of the study was to evaluate the clinical and optical coherence tomography (OCT) findings of patients with choroidal neovascularization (CNV) due to best vitelliform macular dystrophy (BVMD). Methods: Six eyes that were diagnosed with CNV associated with BVMD were evaluated retrospectively. A standard ophthalmologic examination, a fundus fluorescein angiography (FA), and the OCT findings of the patients were examined. Anatomical and functional changes seen after treatment were evaluated. Results: One (16%) of the cases was female and five (83%) were male. The mean age was calculated as 36.3±24.9 years (range 11–73 years). The mean follow-up period of the cases after detecting CNV was determined as 26 months (range 6–168 months). Best corrected visual acuities were 0.65±0.39 logMAR (1.0–0.2 logMAR) when CNV was detected and 0.42±0.25 logMAR (limits 0.7–0.2 logMAR) at the end of the follow-up. Photodynamic therapy was applied to one (17%) of the cases, and intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment was applied to the others (83%). The mean number of intravitreal injections was found to be 3±1.37 (range 2–4). In all cases, intraretinal fluid (IRF), subretinal fluid (SRF), external limiting membrane, and irregularities in inner retinal layers were observed in the initial OCT examinations. In all cases, it was observed that the IRF regressed with treatment and SRF continued in five eyes. Hypertrophic outer retinal scarring developed in all cases. Conclusion: In cases with CNV due to BVMD, regression in CNV activity was achieved with intravitreal anti-VEGF injection treatment. The IRF is a marker that can be used both in the diagnosis and treatment monitoring of CNV associated with BVMD.

🔖

Cite This Article

ADİYEKE, S. K., TÜRE, G. (2022). Choroidal Neovascularization Associated with Best Vitelliform Macular Dystrophy. BEYOGLU EYE JOURNAL, Cilt: 7 - Sayı: 2, 103–108. https://ajindex.com/articles/649037

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Marmorstein AD, Marmorstein LY, Rayborn M, Xinxing W, Hollyfield JG, Ptrukhin K. Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci 2000;97:12758–63
  2. Blodi CF, Stone EM. Best’s vitelliform dystrophy. Ophthalmic Paediatr Genet 1990;11:49–59
  3. Spaide RF, Noble K, Morgan A, Freud KB. Vitelliform macular dystrophy. Ophthalmology 2006;113:1392–400
  4. Gass JD. Stereoscopic atlas of macular diseases. Diagnosis and treatment. Arch Ophthalmol 1989;107:26
  5. Tsang SH, Sharma T. Best vitelliform macular dystrophy. Adv Exp Med Biol 2018;1085:79–90
  6. Viola F, Villani E, Mapelli C, Staurenghi G, Ratiglia R. Bilateral juvenile choroidal neovascularization associated with Best’s vitelliform dystrophy: Observation versus photodynamic therapy. J Pediatr Ophthalmol Strabismus 2010;47:121–2
  7. Andrade RE, Farah ME, Costa RA. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol 2003;136:1179–81
  8. Leu J, Schrage NF, Degenring RF. Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2007;45:1723–5
  9. Khan KN, Mahroo OA, Islam F, Webster AR, Moore AT, Michaelides M. Functional and anatomical outcomes of choroidal neovascularization complicating BEST1-related retinopathy. Retina 2017;37:1360–70
  10. Schatz P, Bitner H, Sander B, Holfort S, Andreasson S, Larsen M, et al. Evaluation of macular structure and function by OCT and electrophysiology in patients with vitelliform macular dystrophy due to mutations in BEST1. Invest Ophthalmol Vis Sci 2010;51:4754–65
  11. Alisa-Victoria K, Jin-Poi T, Shatriah I, Zunaina E, Ngah NF. Choroidal neovascularization secondary to Best’s vitelliform macular dystrophy in two siblings of a Malay family. Clin Ophthalmol 2014;12:537–42
  12. Marano F, Deutman AF, Leys A, Aandekerk AL. Hereditary retinal dystrophies and choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2000;238:760–764
  13. Mandal S, Sinha S, Venkatesh P, Vashisht N. Intravitreal bevacizumab in choroidal neovascularization associated with Best’s vitelliform dystrophy. Indian J Ophthalmol 2011;59:262–3
  14. Cennamo G, Cesarano I, Vecchio EC, Reibaldi M, Crecchio G. Functional and anatomic changes in bilateral choroidal neovascularization associated with vitelliform macular dystrophy